{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T08:26:23Z","timestamp":1786782383067,"version":"build-2736575974"},"posted":{"date-parts":[[2026,1,20]]},"group-title":"Physiology","reference-count":75,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"name":"Garthe and Grace L. Brown Fund and the John E. and Robin Jaqua Fund at the Oregon Community Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,8,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>\n                  Our aim was to determine whether selective pharmacological blockade of GPR39 by the novel drug, VC108, reduces no reflow (NRV) and infarct (INV) volumes during acute myocardial infarction (AMI). Immuocytochemistry and qPCR of isolated rat cardiac cells as well as immunohistochemistry and western blot of rat myocardium was performed for presence of GPR39. Rats underwent 1 h of coronary occlusion and 1 h of reperfusion. Groups 1 and 2 animals received drug\/vehicle prior to or during coronary occlusion. Groups 3 and 4 received drug\/vehicle 5 min prior to or 30 min after reperfusion. Readouts also included tissue pO\n                  <jats:sub>2<\/jats:sub>\n                  , hemodynamics, and wall thickening. In Groups 5 and 6 animals, drug was injected for measurement of plasma and tissue levels. Immunocytochemistry and qPCR of cells and immunohistochemistry and western blot of tissue revealed GPR39 expression in all cardiac cells analyzed as well as entire myocardial tissue. There was marked reduction in NRV and INV in groups 1 and 3 animals where both were measured and in Group 2 where INV was measured. In contrast, Group 4 animals failed to show reduction in NRV and INV with the drug. The reduction in NRV in all animals was associated with higher tissue pO\n                  <jats:sub>2<\/jats:sub>\n                  in VC108 compared to vehicle treated animals. Similar results were obtained for INV in only in Group 2 animals. In Group 3 animals direct cardiomyocyte effect of VC108 was seen in myocardium as evidenced by reduced necrosis and apoptosis. We conclude that VC108 is very effective in reducing INV and NRV in an AMI model when given before coronary occlusion or just prior to reperfusion (the latter being clinically more relevant) both in male and female rats. This effect is not seen after reperfusion. VC108 acts by blocking GPR39, resulting in vasodilation through pericyte and VSMC relaxation. It also directly protects cardiomyocytes by preventing downstream effects of GPR39 stimulation.\n                <\/jats:p>\n                <jats:sec>\n                  <jats:title>New and Noteworthy<\/jats:title>\n                  <jats:p>GPR39 is the receptor for 15-HETE, which is a vasoconstrictor with direct cardiomyocyte detrimental effects. Pharmacological inhibition of GPR39 by a novel inhibitor, VC108, reduces coronary no reflow after acute myocardial infarction by relaxing contracted pericytes surrounding capillaries, whereby increasing oxygen delivery. GPR39 inhibition also reduces necrosis and ferroptosis by interrupting aberrant downstream signaling responsible for cell death. Hence, pharmacological inhibition of GPR39 by VC108 offers a novel treatment of acute myocardial infarction.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Graphical Abstract<\/jats:title>\n                  <jats:p>\n                    Proposed mechanism of action of VC108 when given prior to and during coronary occlusion based on our results. The drug inhibits the action of the vasoconstrictor, 15-HETE, on GPR39. This causes vasodilation by relaxing contracted pericytes and increasing capillary perfusion, resulting in increased tissue pO\n                    <jats:sub>2<\/jats:sub>\n                    and reduction in no reflow (left side). When tissue pO\n                    <jats:sub>2<\/jats:sub>\n                    is not associated with necrosis, GPR39 inhibition by VC108 directly affects cardiomyocytes by inhibiting downstream signaling of GPR39 present in cardiomyocytes that can lead to cell injury and death. Hence, less necrosis and apoptosis are noted in VC108 versus vehicle treated animals. Created in\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/BioRender.com\">https:\/\/BioRender.com<\/jats:ext-link>\n                    .\n                  <\/jats:p>\n                  <jats:fig id=\"ufig1\" position=\"float\" orientation=\"portrait\" fig-type=\"figure\">\n                    <jats:graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"699339v2_ufig1\" position=\"float\" orientation=\"portrait\"\/>\n                  <\/jats:fig>\n                <\/jats:sec>","DOI":"10.64898\/2026.01.16.699339","type":"posted-content","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T03:45:12Z","timestamp":1768967112000},"source":"Crossref","is-referenced-by-count":0,"title":["Selective Pharmacological Blockade of GPR39 Markedly Reduces No Reflow and Infarct Volumes in a Rat Acute Myocardial Infarction When Administered Prior to Reperfusion"],"prefix":"10.64898","author":[{"given":"Carmen","family":"Methner","sequence":"first","affiliation":[{"name":"Knight Cardiovascular Institute, Oregon Health & Science University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Plascencia","sequence":"additional","affiliation":[{"name":"Knight Cardiovascular Institute, Oregon Health & Science University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allura","family":"Thompson","sequence":"additional","affiliation":[{"name":"Knight Cardiovascular Institute, Oregon Health & Science University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Anesthesia and Perioperative Medicine, Oregon Health & Science University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Kajimoto","sequence":"additional","affiliation":[{"name":"Knight Cardiovascular Institute, Oregon Health & Science University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Elizabeth","family":"Le","sequence":"additional","affiliation":[{"name":"Knight Cardiovascular Institute, Oregon Health & Science University"},{"name":"Veterans Administration Portland Health Care System, Oregon Health & Science University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostino","family":"Cianciulli","sequence":"additional","affiliation":[{"name":"the Medical Research Center, Aptuit (Evotec), Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Pellacani","sequence":"additional","affiliation":[{"name":"the Medical Research Center, Aptuit (Evotec), Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Franchi","sequence":"additional","affiliation":[{"name":"the Medical Research Center, Aptuit (Evotec), Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Marcheselli","sequence":"additional","affiliation":[{"name":"the Medical Research Center, Aptuit (Evotec), Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Parazzoli","sequence":"additional","affiliation":[{"name":"the Medical Research Center, Aptuit (Evotec), Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Micheli","sequence":"additional","affiliation":[{"name":"the Medical Research Center, Aptuit (Evotec), Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0124-3920","authenticated-orcid":false,"given":"Sanjiv","family":"Kaul","sequence":"additional","affiliation":[{"name":"Knight Cardiovascular Institute, Oregon Health & Science University"},{"name":"Vasocardea, Inc. Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026081500450931000_2026.01.16.699339v2.1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00454.2021"},{"key":"2026081500450931000_2026.01.16.699339v2.2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00312.20"},{"key":"2026081500450931000_2026.01.16.699339v2.3","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M407676200"},{"key":"2026081500450931000_2026.01.16.699339v2.4","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-010-0517-1"},{"key":"2026081500450931000_2026.01.16.699339v2.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2010.06.019"},{"key":"2026081500450931000_2026.01.16.699339v2.6","doi-asserted-by":"publisher","DOI":"10.1042\/BST20220271"},{"key":"2026081500450931000_2026.01.16.699339v2.7","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00242.2014"},{"key":"2026081500450931000_2026.01.16.699339v2.8","doi-asserted-by":"crossref","unstructured":"Aydo\u011fdu S , Pepanian C , Rathod DC , Schulz F , Imhof D . Physiological functions and structural features of G\u03b112\/13 proteins. Biomed. Pharmacother. 2025;191:118523.","DOI":"10.1016\/j.biopha.2025.118523"},{"key":"2026081500450931000_2026.01.16.699339v2.9","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2011.00051"},{"key":"2026081500450931000_2026.01.16.699339v2.10","doi-asserted-by":"crossref","unstructured":"Guo P , Tai Y , Wang M , Sun H , Zhang L , Wei W , Xiang YK , Wang Q . G\u03b112 and G\u03b113: Versatility in Physiology and Pathology. Front. Cell. Dev. Biol. 2022;10:809425.","DOI":"10.3389\/fcell.2022.809425"},{"key":"2026081500450931000_2026.01.16.699339v2.11","unstructured":"Methner C , Liu L , Thompson A , Plascencia M , Chakravarty P , Kaul S . GPR39 depletion Prevents Development of Pulmonary Arterial Hypertension by Attenuating Hypoxia-induced Aberrant signaling. Circulation (abstract)"},{"key":"2026081500450931000_2026.01.16.699339v2.12","first-page":"e202500662","article-title":"Identification of Novel and selective GPR39 receptor antagonists for the treatment of Acute Myocardial Ischemia. Chem","volume":"21","year":"2026","journal-title":"Med. Chem"},{"key":"2026081500450931000_2026.01.16.699339v2.13","doi-asserted-by":"crossref","unstructured":"Le DE , Kajimoto M , Zhao Y , Methner C , Cianciulli A , Semeraro T , Trist IML , Micheli F , Kaul S. 15-Hydroxyeicosatetraenoic acid and GPR39 together orchestrate coronary autoregulation: a comprehensive metabolomic analysis. https:\/\/www.biorxiv.org\/cgi\/content\/short\/2025.12.23.696315v1","DOI":"10.64898\/2025.12.23.696315"},{"key":"2026081500450931000_2026.01.16.699339v2.14","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-9022197\/v1"},{"key":"2026081500450931000_2026.01.16.699339v2.15","doi-asserted-by":"crossref","first-page":"8835","DOI":"10.1038\/s41598-022-12749-6","article-title":"Proteomic Profiling of Concurrently Isolated Primary Microvascular Endothelial Cells, Pericytes, and Smooth Muscle Cells from Adult Mouse Heart","volume":"12","year":"2022","journal-title":"Sci. Rep"},{"key":"2026081500450931000_2026.01.16.699339v2.16","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.627091"},{"key":"2026081500450931000_2026.01.16.699339v2.17","first-page":"8756","article-title":"Two new \u201cprotected\u201d oxyphors for biological oximetry: properties and application in tumor imaging","volume":"83","year":"2001","journal-title":"Anal. Chem"},{"key":"2026081500450931000_2026.01.16.699339v2.18","doi-asserted-by":"publisher","DOI":"10.1021\/am9001698"},{"key":"2026081500450931000_2026.01.16.699339v2.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0894-7317(14)80100-4"},{"key":"2026081500450931000_2026.01.16.699339v2.20","first-page":"H891","article-title":"Guidelines for evaluating myocardial cell death","volume":"317","year":"2019","journal-title":"Am J Physiol"},{"key":"2026081500450931000_2026.01.16.699339v2.21","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00021.2001"},{"key":"2026081500450931000_2026.01.16.699339v2.22","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000255173.50317.fc"},{"issue":"11","key":"2026081500450931000_2026.01.16.699339v2.23","first-page":"e0161629","article-title":"Hulten LM The Arachidonate 15-Lipoxygenase Enzyme Product 15-HETE Is Present in Heart Tissue from Patients with Ischemic Heart Disease and Enhances Clot Formation","volume":"23","year":"2016","journal-title":"PLoS One"},{"key":"2026081500450931000_2026.01.16.699339v2.24","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.echo.2019.05.012","article-title":"Therapeutic Ultrasound Increases Myocardial Blood Flow in Ischemic Myocardium and Cardiac Endothelial Cells: Results of In-vivo and In-Vitro Experiments","volume":"32","year":"2019","journal-title":"J. Am. Soc. Echocardiogr"},{"key":"2026081500450931000_2026.01.16.699339v2.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardiores.2003.09.031"},{"key":"2026081500450931000_2026.01.16.699339v2.26","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.121.319478"},{"key":"2026081500450931000_2026.01.16.699339v2.27","doi-asserted-by":"crossref","first-page":"1078205","DOI":"10.3389\/fphar.2023.1078205","article-title":"Dapagliflozin alleviates myocardial ischemia\/reperfusion injury by reducing ferroptosis via MAPK signaling inhibition","volume":"14","year":"2023","journal-title":"Front. Pharmacol"},{"key":"2026081500450931000_2026.01.16.699339v2.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.yjmcc.2005.01.012"},{"key":"2026081500450931000_2026.01.16.699339v2.29","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.eng.2024.05.015","article-title":"Activation of the macrophage-associated inflammasome exacerbates myocardial fibrosis Through the 15-HETE-Mediated Pathway in acute myocardial infarction","volume":"42","year":"2024","journal-title":"Engineering"},{"key":"2026081500450931000_2026.01.16.699339v2.30","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.201193398"},{"key":"2026081500450931000_2026.01.16.699339v2.31","doi-asserted-by":"publisher","DOI":"10.1210\/en.2006-0933"},{"key":"2026081500450931000_2026.01.16.699339v2.32","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.3390\/ijms22083872","article-title":"The zinc-sensing receptor GPR39 in physiology and as a pharmacological target","volume":"22","year":"2021","journal-title":"Int. J. Mol. Sci"},{"key":"2026081500450931000_2026.01.16.699339v2.33","doi-asserted-by":"crossref","unstructured":"Cheng Y , Zhao C , Bin Y , Liu Y , Cheng L , Xia F , Tian X , Liu X , Liu S , Ying B , Shao Z , Yan W . The pathophysiological functions and therapeutic potential of GPR39: Focus on agonists and antagonists. Int. Immunopharmacol. 202;143(Pt 3):113491.","DOI":"10.1016\/j.intimp.2024.113491"},{"key":"2026081500450931000_2026.01.16.699339v2.34","doi-asserted-by":"crossref","unstructured":"Zhang L , Song J , Zang Z , Tang H , Li W , Lai S , Deng C . Adaptive evolution of gpr39 in diverse directions in vertebrates. Gen. Comp. Endocrinol. 2020;299:113610.","DOI":"10.1016\/j.ygcen.2020.113610"},{"key":"2026081500450931000_2026.01.16.699339v2.35","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.29280.001"},{"key":"2026081500450931000_2026.01.16.699339v2.36","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00097.2019"},{"key":"2026081500450931000_2026.01.16.699339v2.37","doi-asserted-by":"crossref","first-page":"930492","DOI":"10.3389\/fcvm.2022.930492","article-title":"Persistent Coronary Vasomotor Tone during Myocardial Ischemia Occurs at the Capillary Level and May Involve Pericytes","volume":"9","year":"2022","journal-title":"Front. Cardiovasc. Med"},{"key":"2026081500450931000_2026.01.16.699339v2.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2010.04.015"},{"key":"2026081500450931000_2026.01.16.699339v2.39","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1254\/jjp.37.325","article-title":"Vascular effects of 15-hydroperoxy-eicosatetraenoic acid and 15-hydroxyeicosatetraenoic acid on canine arteries","volume":"37","year":"1985","journal-title":"Jpn. J. Pharmacol"},{"key":"2026081500450931000_2026.01.16.699339v2.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.plefa.2011.10.006"},{"key":"2026081500450931000_2026.01.16.699339v2.41","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1172\/JCI108404","article-title":"Local effects of acute cellular injury on regional myocardial blood flow","volume":"57","year":"1976","journal-title":"J. Clin. Invest"},{"key":"2026081500450931000_2026.01.16.699339v2.42","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1161\/01.RES.36.6.771","article-title":"Reduced myocardial reflow and increased coronary vascular resistance following prolonged myocardial ischemia in the dog","volume":"36","year":"1975","journal-title":"Circ. Res"},{"key":"2026081500450931000_2026.01.16.699339v2.43","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.94.4.748"},{"key":"2026081500450931000_2026.01.16.699339v2.44","first-page":"625","article-title":"The significance of local vascular phenomena in the production of ischemic necrosis in skeletal muscle","volume":"24","year":"1948","journal-title":"Am. J. Pathol"},{"key":"2026081500450931000_2026.01.16.699339v2.45","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(67)90552-1"},{"key":"2026081500450931000_2026.01.16.699339v2.46","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/path.1700780112","article-title":"Renal ischaemia with failed reflow","volume":"78","year":"1959","journal-title":"J. Pathol. Bacteriol"},{"key":"2026081500450931000_2026.01.16.699339v2.47","doi-asserted-by":"publisher","DOI":"10.1002\/path.1700910127"},{"key":"2026081500450931000_2026.01.16.699339v2.48","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.19.1.57"},{"key":"2026081500450931000_2026.01.16.699339v2.49","first-page":"437","article-title":"Cerebral ischemia. II. The no reflow phenomenon","volume":"52","year":"1968","journal-title":"Am. J. Pathol"},{"key":"2026081500450931000_2026.01.16.699339v2.50","doi-asserted-by":"publisher","DOI":"10.1172\/JCI107898"},{"key":"2026081500450931000_2026.01.16.699339v2.51","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2022"},{"key":"2026081500450931000_2026.01.16.699339v2.52","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.29280.001"},{"key":"2026081500450931000_2026.01.16.699339v2.53","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.93.11.1993"},{"key":"2026081500450931000_2026.01.16.699339v2.54","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.89.6.2562"},{"key":"2026081500450931000_2026.01.16.699339v2.55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407024"},{"key":"2026081500450931000_2026.01.16.699339v2.56","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1161\/CIRCULATIONAHA.124.068938","article-title":"Effect of cangrelor on infarct size in ST-segment-elevation myocardial infarction treated by primary percutaneous coronary intervention: a randomized controlled trial (the PITRI trial)","volume":"150","year":"2024","journal-title":"Circulation"},{"key":"2026081500450931000_2026.01.16.699339v2.57","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30072-1"},{"key":"2026081500450931000_2026.01.16.699339v2.58","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1016\/j.jacc.2017.03.601","article-title":"DAMAMI-3 Investigators. Myocardial damage in patients with deferred stenting after STEMI: a DANAMI-3-DEFER substudy","volume":"69","year":"2017","journal-title":"J.Am. Coll. Cardiol"},{"key":"2026081500450931000_2026.01.16.699339v2.59","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.9.1063"},{"key":"2026081500450931000_2026.01.16.699339v2.60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.10.047"},{"key":"2026081500450931000_2026.01.16.699339v2.61","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.545178"},{"key":"2026081500450931000_2026.01.16.699339v2.62","doi-asserted-by":"publisher","DOI":"10.1067\/mje.2003.44"},{"key":"2026081500450931000_2026.01.16.699339v2.63","first-page":"1194","article-title":"Molecular Imaging Identifies Regions with Microthromboemboli During Primary Angioplasty in Acute Coronary Thrombosis","volume":"45","year":"2004","journal-title":"J. Nucl. Med"},{"key":"2026081500450931000_2026.01.16.699339v2.64","doi-asserted-by":"publisher","DOI":"10.2310\/JIM.0b013e318279b7f6"},{"key":"2026081500450931000_2026.01.16.699339v2.65","doi-asserted-by":"publisher","DOI":"10.3310\/eme03090"},{"key":"2026081500450931000_2026.01.16.699339v2.66","doi-asserted-by":"publisher","DOI":"10.1253\/circj.67.295"},{"key":"2026081500450931000_2026.01.16.699339v2.67","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2020.601324"},{"key":"2026081500450931000_2026.01.16.699339v2.68","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.10375"},{"key":"2026081500450931000_2026.01.16.699339v2.69","first-page":"382086","article-title":"Short-term effects of verapamil and diltiazem in the treatment of no reflow phenomenon: a meta-analysis of randomized controlled trials","volume":"2015","year":"2015","journal-title":"Biomed. Res. Int"},{"key":"2026081500450931000_2026.01.16.699339v2.70","doi-asserted-by":"crossref","first-page":"e011408","DOI":"10.1161\/CIRCINTERVENTIONS.121.011408","article-title":"Karim M Comparison of intracoronary epinephrine and adenosine for no-reflow in normotensive patients with acute coronary syndrome (COAR trial)","volume":"15","year":"2022","journal-title":"Circ. Cardiovasc. Interv"},{"key":"2026081500450931000_2026.01.16.699339v2.71","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.amjcard.2024.07.011","article-title":"Efficiency and safety of intracoronary epinephrine administration in patients with ST-elevation myocardial infarction with refractory coronary no-reflow","volume":"226","year":"2024","journal-title":"Am. J. Cardiol"},{"key":"2026081500450931000_2026.01.16.699339v2.72","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw136"},{"key":"2026081500450931000_2026.01.16.699339v2.73","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(99)00418-0"},{"key":"2026081500450931000_2026.01.16.699339v2.74","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.02.061"},{"key":"2026081500450931000_2026.01.16.699339v2.75","first-page":"CD009503","article-title":"Adenosine and verapamil for no-reflow during primary percutaneous coronary intervention in people with acute myocardial infarction","volume":"2015","year":"2015","journal-title":"Cochrane. Database. Syst. Rev"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.01.16.699339","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T07:45:22Z","timestamp":1786779922000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.64898\/2026.01.16.699339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":75,"URL":"https:\/\/doi.org\/10.64898\/2026.01.16.699339","relation":{},"subject":[],"published":{"date-parts":[[2026,1,20]]},"subtype":"preprint"}}